First test of new cancer pill targets advanced tumors
Disease control
Completed
This first-in-human study tested a new oral drug called RP903 in people with advanced cancers that had stopped responding to standard treatments. The main goals were to find a safe dose and see how the body processes the drug. The study focused on specific cancers, including ovar…
Phase: PHASE1 • Sponsor: Risen (Suzhou) Pharma Tech Co., Ltd. • Aim: Disease control
Last updated Mar 30, 2026 14:34 UTC